Prior studies have reported that Pb exposure results in enhanced sensitivity to both D1 and D2 dopamine agonists as indicated by left shifts of the dose-effect functions for the discrimination of these agonists from saline in drug discrimination procedures (Cory-Slechta and Widzowski, 1991). To further determine mechanisms of such Pb-induced changes in dopamine system functions, this study evaluated the potential contribution to Pb-induced D1 supersensitivity of:i) synergistic D1-D2 receptor interactions, and ii) the effects of the chronic D1 agonist administration inherent in the drug discrimination procedures themselves. As in Cory-Slechta and Widzowski (1991), rats exposed from weaning to 50 or 150 ppm Pb acetate in drinking water and trained using standard operant drug discrimination procedures to discriminate 6.0 mg/kg of the partial D1 agonist SKF38393 from saline showed greater sensitivity to SKF38393 (left-shifted dose effect curves) than did the 0 ppm group. To determine the role of D1/D2 interactions in this supersensitivity, SKF38393 dose-effect curves of the groups were compared in the presence and absence of a dose of 0.04 mg/kg of the D2 antagonist haloperidol. The impact of the chronic administration of the D1 agonist utilized in drug discrimination training was determined by comparing the dose-effect curves of the groups before and after a 24 day period of discontinuation of drug discrimination training. D1/D2 interactions do not appear to contribute to Pb-induced enhancement of sensitivity to the D1 agonist SKF38393, as it was maintained even in the presence of the D2 antagonist haloperidol. Discontinuation of drug discrimination training resulted in sensitization in control but not Pb-treated rats, a pattern indicative of Pb-induced D1 subsensitivity. These data raise questions about the depletion of dopamine (DA) availability as a mechanism of Pb-induced alterations in DA system function and suggest that Pb-induced D1 supersensitivity may represent altered effects of chronic D1 administration imposed on DA systems modified by Pb exposure per se.

Download full-text PDF

Source

Publication Analysis

Top Keywords

drug discrimination
28
discrimination training
16
discrimination procedures
12
changes dopamine
8
discrimination
8
procedures cory-slechta
8
cory-slechta widzowski
8
widzowski 1991
8
pb-induced supersensitivity
8
effects chronic
8

Similar Publications

Comprehensive Analysis of Metabolic Changes in Mice Exposed to Corilagin Based on GC-MS Analysis.

Drug Des Devel Ther

January 2025

Department of Neurosurgery, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, 272000, People's Republic of China.

Background: Corilagin is widely distributed in various medicinal plants. In recent years, numerous pharmacological activities of Corilagin have been reported, including anti-inflammatory, antiviral, hepatoprotective, anti-tumor, and anti-fibrosis effects. However, there is still a need for systematic metabolomics analysis to further elucidate its mechanisms of action.

View Article and Find Full Text PDF

Development and validation of a prognostic nomogram for predicting of patients with acute sedative-hypnotic overdose admitted to the intensive care unit.

Sci Rep

January 2025

Emergency Medicine Laboratory and the Department of Emergency, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, Sichuan, China.

To develop and evaluate a predictive model for intensive care unit (ICU) admission among patients with acute sedative-hypnotic overdose. We conducted a retrospective analysis of patients admitted to the emergency department of West China Hospital, Sichuan University, between October 11, 2009, and December 31, 2023. Patients were divided into ICU and non-ICU groups based on admission criteria including the need for blood purification therapy, organ support therapy (ventilatory support, vasoactive drugs, renal replacement therapy, artificial liver), or post-cardiopulmonary resuscitation.

View Article and Find Full Text PDF

Human organotypic colon in vitro microtissue: unveiling a new window into colonic drug disposition.

Eur J Pharm Sci

January 2025

Preclinical Sciences & Translational Safety, Janssen R&D, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address:

The purpose of this study was to evaluate EpiColon, a novel human organotypic 3D colon microtissue prototype, developed to assess colonic drug disposition, with a particular focus on permeability ranking, and compare its performance to Caco-2 monolayers. EpiColon was characterized for barrier function using transepithelial electrical resistance (TEER), morphology via histology and immunohistochemistry, and functionality through drug transport studies measuring apparent permeability (P). Cutoff thresholds for the permeability of FITC-dextran 4 kDa (FD4), FITC-dextran 10 kDa (FD10S), and [C]mannitol were established to monitor microtissue integrity.

View Article and Find Full Text PDF

Pathogenic intracellular bacteria pose a significant threat to global public health due to the barriers presented by host cells hindering the timely detection of hidden bacteria and the effective delivery of therapeutic agents. To address these challenges, we propose a tandem diagnosis-guided treatment paradigm. A supramolecular sensor array is developed for simple, rapid, accurate, and high-throughput identification of intracellular bacteria.

View Article and Find Full Text PDF

Objective: To develop and validate a prognostic model for risk-stratified monitoring of 5-aminosalicylate nephrotoxicity.

Methods: This UK retrospective cohort study used data from the Clinical Practice Research Datalink Aurum and Gold for model development and validation respectively. It included adults newly diagnosed with inflammatory bowel disease and established on 5-aminosalicylic acid (5-ASA) treatment between 1 January 2007 and 31 December 2019.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!